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Rationale: Lung fibroblasts are implicated in respiratory disease pathology including chronic obstructive 
pulmonary disease (COPD).  Phenotypic differences between fibroblasts isolated from the bronchi 
versus the lung parenchyma have been described but no studies have compared the cell types on a 
genome wide scale. DNA methylation is a reversible modification of DNA structure with the ability to 
affect cell function via the alteration of gene expression. Here we compared genome wide DNA 
methylation profiles from bronchial and lung fibroblasts and assessed modification to these profiles in 
cells isolated from individuals with COPD.  
Methods: DNA was isolated from lung (LgF) and bronchial fibroblasts (BrF) at passage 4 and bisulphite 
treated. Site specific, quantitative genome wide methylation was determined using the Illumina 450K 
Infinium Methylation BeadChip array. Linear modelling and DMRcate functions identified differentially 
methylated sites and regions respectively between BrF and LgF and from cells isolated from healthy 
individuals versus those with COPD.  
Results: 3980 CpG (methylation) sites significantly differed (Bonferroni correction) between BrF and LgF 
isolated from healthy individuals. These sites had a broad distribution of effect size, with 240 CpG sites 
displaying a difference in methylation of >50%.  78 of these sites validated in a second cohort of 
matched BrF and LgF isolated from the same individual. There was genomic proximity to these sites and 
DMRcate was used to refine the individual CpG sites to 5 regions of interest associated with 5 genes; 
HLX, TWIST1, CREB5, SKAP2 and PRDM16. Differences in methylation were less pronounced when 
comparing cells isolated from healthy individuals to those with COPD. In BrF 47 DMRcate regions were 
identified with a maximum difference in methylation of at least 20%.   In LgF 3 DMRcate regions were 
identified with a maximum difference in methylation of at least 20%.   
Conclusions: DNA methylation profiles are significantly different between BrF and LgF but only small 
modifications are associated with COPD.  Future work will focus on validating a methylation based 
marker of lung versus bronchial fibroblasts and associating our differential observations with 
gene/protein expression. 
 
 
